Peptide education
Setmelanotide
Imcivree · RM-493 · MC4R agonist · alpha-MSH analog
Setmelanotide is an approved peptide drug, sold as Imcivree, that activates the melanocortin-4 receptor in the brain's hunger and energy pathway. It works by replacing a signal that specific rare diseases knock out: acquired hypothalamic obesity, Bardet-Biedl syndrome, and obesity tied to POMC, PCSK1, or LEPR deficiency. That is why the approval is real and the internet reputation is wrong at the same time: the label explicitly excludes general polygenic obesity, which is what most people mean by weight loss.
Setmelanotide is one of the few genuinely approved peptides, and its label is a fence, not a launchpad: it treats named rare MC4-pathway diseases and explicitly not ordinary obesity. Outside those diagnoses, the evidence does not follow the molecule.
Overview
Quick answer
Setmelanotide is not a general weight-loss peptide. The Imcivree label is narrow: it applies to specific MC4-pathway rare-obesity conditions, not ordinary polygenic obesity, benign variants, cosmetic body-composition goals, tanning, libido, or research-vial claims.
What is setmelanotide?
An eight-amino-acid cyclic peptide that activates the MC4 receptor, part of the brain pathway governing hunger, satiety, and energy expenditure. The approved product, Imcivree, reduces excess body weight and maintains that reduction in specific rare obesity conditions.
What is it actually approved for?
Adults and children 4 years and older with acquired hypothalamic obesity, and patients 2 years and older with Bardet-Biedl syndrome or with POMC, PCSK1, or LEPR deficiency meeting the label's genetic-testing criteria. Nothing broader.
What dose and schedule show up in the label?
Once-daily subcutaneous injection, titrated by diagnosis, age, tolerability, and kidney function. For many patients 6 and older, maintenance centers on 3 mg once daily when tolerated.
Why do people confuse it with ordinary weight-loss peptides?
Because the outcome is weight reduction and the mechanism touches appetite. What gets dropped on the way to the forums is the diagnosis: the FDA label excludes general polygenic obesity and every obesity type outside its named conditions.
What is easy to overgeneralize?
The approval itself. Real approval plus rare-disease trial data does not transfer to wellness weight loss, peptide stacks, tanning, libido, or any non-approved vial using the setmelanotide name.
Reported practice
Commonly reported protocol
Label-pattern specialty use. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
FDA and DailyMed lay out Imcivree's use for acquired hypothalamic obesity, Bardet-Biedl syndrome, and POMC, PCSK1, or LEPR deficiency, with label criteria and age cutoffs.
The label says Imcivree is not indicated for obesity outside acquired hypothalamic obesity, BBS, or POMC, PCSK1, or LEPR deficiency, including general polygenic obesity.
The original rare-genetic-obesity approval drew on small one-year studies in severe obesity due to POMC, PCSK1, or LEPR pathway deficiency.
FDA describes a 66-week BBS trial with a 14-week randomized, double-blind, placebo-controlled period followed by open-label treatment.
Important label issues include sexual-arousal disturbance, depression and suicidal ideation monitoring, hypersensitivity, skin pigmentation and nevi monitoring, acquired-HO adrenal and sodium issues, and renal-exposure considerations.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Setmelanotide is FDA-approved for weight management. | True only with the diagnosis attached. Imcivree is approved for reducing excess body weight and maintaining weight reduction long term in the label's acquired hypothalamic obesity, BBS, and POMC, PCSK1, or LEPR deficiency populations. | The MC4 receptor pathway helps regulate hunger, satiety, and energy expenditure, which fits those rare disease contexts when MC4-pathway activity is insufficient. | Internet weight-loss discussion often shortens the claim to "an approved peptide for weight loss." That skips the disease context, age criteria, product controls, and label limitations. | Accurate only for Imcivree inside the label. It becomes misleading when used as a blanket claim for ordinary obesity, wellness weight loss, peptide stacks, or non-approved setmelanotide products. |
| Setmelanotide treats ordinary obesity. | The human evidence is in rare, defined populations. The label says the drug is not indicated for general polygenic obesity or obesity unrelated to acquired hypothalamic obesity, BBS, or the named pathway deficiencies. | MC4 activation can reduce food intake and affect energy expenditure. The evidence and label apply to specific genetic or acquired hypothalamic conditions in which that pathway has been tested. | Weight-loss forums and peptide-market discussions may treat any appetite or weight signal as transferable, but setmelanotide's evidence is specific to the diagnosed populations in its clinical program and label. | The label points to rare-disease obesity care, not general obesity or cosmetic fat-loss use. |
| The POMC, PCSK1, and LEPR pathway data are strong. | FDA's 2020 approval announcement and the Lancet Diabetes & Endocrinology phase 3 paper support human evidence in severe obesity due to those pathway deficiencies, with one-year treatment in very small rare-disease cohorts. | POMC, PCSK1, and LEPR biology sits upstream of MC4 receptor signaling, so an MC4 agonist has a direct disease-pathway rationale in these diagnoses. | When rare-disease results show up in ordinary weight-loss claims, the diagnosis has usually been stripped out. | Strong for the named rare pathway-deficiency setting, weak as support for broader weight-loss claims. |
| Setmelanotide has Bardet-Biedl syndrome evidence. | FDA's BBS supplement and the phase 3 BBS and Alstrom syndrome paper support a BBS-specific use. FDA described an initial placebo-controlled period followed by open-label treatment, with BMI reduction after 52 weeks. | BBS is a syndromic obesity condition connected to impaired satiety and early-onset progressive obesity. MC4-pathway activation is relevant to that disease biology, but the claim depends on the BBS evidence. | Online melanocortin discussion can blur BBS, tanning peptides, libido peptides, and fat-loss products. BBS is a medical diagnosis, not a melanocortin marketing category. | Supported for BBS-specific chronic weight management under the Imcivree label, not for unrelated syndromic obesity or broad weight-loss use. |
| Research-market setmelanotide is equivalent to Imcivree. | The human evidence and warnings are attached to Imcivree and clinical trial material, not every vial, compounded product, clinic supply, or vendor listing using the setmelanotide name. | This is not an MC4 receptor issue. It is a product-quality issue involving identity, concentration, sterility, endotoxin control, storage, labeling, and adverse-event reporting. | A vendor label, purity statement, or user report can make the molecule sound familiar while still missing Imcivree-level concentration, storage, monitoring, and adverse-event tracking. | The generic name is not the product. Imcivree evidence comes from a labeled 10 mg/mL sterile vial, defined storage, rare-disease selection, and monitored clinical use. |
Bottom line
Main takeaway
Setmelanotide is a prescription drug for rare genetic and hypothalamic obesity, not a fat-loss peptide. The diagnosis matters as much as the molecule.
This is a different category from GLP-1 drugs and cutting-cycle products: it restores an under-signaled pathway in defined diseases. Its clearest evidence lives inside those diagnoses, and the label says so in writing.
The current DailyMed label defines the approved context. FDA's approval announcements, the POMC/LEPR phase 3 paper, the BBS/Alstrom phase 3 paper, and the patient-reported outcomes paper each supply a distinct slice of the record.
Identity
What it is
Setmelanotide is a cyclic alpha-MSH analog that activates the melanocortin-4 receptor. As Imcivree it comes as a 10 mg/mL solution in a multiple-dose vial for daily subcutaneous injection.
Its logic is replacement, not suppression: in POMC, PCSK1, or LEPR deficiency, in hypothalamic injury, and in Bardet-Biedl syndrome, the MC4 pathway is under-signaled, and the drug pushes signaling back toward normal. Ordinary obesity has no such missing signal, which is why the label excludes it.
That distinction is what internet discussion flattens. The trials and the label describe rare diagnostic settings with small cohorts, and nothing in them supports general weight-loss, body-composition, tanning, or libido use.
How people talk about it online
Online, setmelanotide gets compressed into MC4R weight loss. That framing drops the one fact that defines the drug: the label excludes general polygenic obesity and other non-labeled obesity types.
Melanocortin talk also bleeds into melanotan, tanning, and libido territory. Setmelanotide's approved use is rare-obesity medicine, and its pigmentation and nevi effects are a monitored label safety issue, not a cosmetic feature.
Product claims need their own proof. A non-approved vial using the same name still has to document concentration, sterility, storage, labeling, excipients, and oversight before Imcivree's evidence is even relevant to it.
Use context
Routes, doses, and cycle patterns
The Imcivree label and rare-disease studies define the documented use context. The route is subcutaneous injection, the frequency is once daily, and the label uses age-, indication-, tolerance-, and renal-function-based titration. The cited sources do not establish an ordinary-weight-loss course length.
Human studies and product labels
Current Imcivree label, acquired hypothalamic obesity
- Purpose
- Reduce excess body weight and maintain weight reduction long term
- Context
- FDA label
- Route
- Subcutaneous injection per label
- Amount
- 0.5 mg once daily starting dose; 3 mg once daily maintenance for ages 6 and older if tolerated
- Frequency
- Once daily per label; timing details belong in the prescribing information
- Duration
- Label describes long-term maintenance after titration, not a short-cycle schedule
The label covers adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity. It also includes acquired-HO safety issues such as acute adrenal insufficiency and sodium imbalance in patients with central diabetes insipidus or AVP deficiency.
Current Imcivree label, BBS or POMC, PCSK1, or LEPR deficiency
- Purpose
- Chronic weight management in label-defined syndromic or monogenic obesity
- Context
- FDA label
- Route
- Subcutaneous injection per label
- Amount
- 2 mg starting dose for ages 12 and older; 1 mg for ages 6 to less than 12; 0.5 mg for ages 2 to less than 6
- Frequency
- Once daily
- Duration
- Starting dose for two weeks, then titration if tolerated; maintenance is 3 mg once daily for ages 6 and older
The label separates patient selection by diagnosis and genetics. It also changes dosing for younger children, severe renal impairment, and tolerability during titration.
POMC, PCSK1, and LEPR deficiency phase 3 program
- Purpose
- Severe obesity due to rare MC4-pathway deficiency
- Context
- Open-label multicentre phase 3 trials and FDA approval context
- Route
- Subcutaneous
- Amount
- Titrated setmelanotide in the trial program; current label dosing depends on diagnosis, age, tolerability, and renal function
- Frequency
- Once daily in the approved-product treatment pattern
- Duration
- One-year studies in FDA's 2020 approval description
FDA described two one-year studies and effectiveness by the proportion of patients who lost more than 10 percent of body weight after a year. These were very small rare-disease cohorts, not common obesity trials.
Bardet-Biedl syndrome phase 3 program
- Purpose
- Chronic weight management in BBS
- Context
- Randomized, double-blind, placebo-controlled phase 3 period followed by open-label treatment
- Route
- Subcutaneous
- Amount
- Titrated setmelanotide in the trial program; current label dosing depends on diagnosis, age, tolerability, and renal function
- Frequency
- Once daily in the approved-product treatment pattern
- Duration
- 66-week trial with 14-week randomized period and 52-week open-label period
FDA reported average BMI reduction after 52 weeks and responder proportions for 5 percent and 10 percent BMI reduction. That is BBS-specific evidence, not a generic melanocortin weight-loss claim.
Real-world discussion
Label-pattern specialty use
- Purpose
- Rare genetic obesity treatment
- Context
- Specialty clinical prescribing
- Route
- Subcutaneous injection
- Amount
- Use follows the label's weight- and age-based daily titration
- Frequency
- Once daily per label
- Duration
- Chronic per label
Setmelanotide is an approved drug for specific rare genetic obesity syndromes, prescribed through specialty channels. There is no community protocol, and off-label chatter around it for general weight loss has no evidence basis. These are reported patterns, not recommendations.
What varies
- Diagnosis: acquired hypothalamic obesity, BBS, and POMC, PCSK1, or LEPR deficiency are the label limit; general obesity does not supply the same MC4-pathway rationale.
- Age: the label uses different starting amounts for younger children, older children, and adults.
- Tolerability: the label titrates after the starting period when the starting amount is tolerated.
- Renal function: severe renal impairment changes exposure and label recommendations.
- Product: Imcivree's concentration, storage, excipients, sterile manufacturing, and labeling are not guaranteed by non-approved vials.
Human data
Human evidence
The human record is concrete and narrow. FDA's 2020 approval rested on two one-year studies in severe obesity from POMC, PCSK1, or LEPR deficiency, scored by the share of patients losing at least 10 percent of body weight. The 2022 Bardet-Biedl supplement added a 66-week trial with a 14-week placebo-controlled period and average BMI reduction after 52 weeks. These were very small rare-disease cohorts, right for the conditions and silent on ordinary obesity. The label states that boundary explicitly.
Evidence maturity
Setmelanotide is a genuinely approved peptide, but only for specific rare MC4-pathway obesities, with general weight loss explicitly outside the label.
An MC4 receptor agonist designed to restore signaling where leptin-melanocortin pathway defects drive severe obesity.
Small one-year studies in POMC, PCSK1, and LEPR deficiency produced clinically meaningful weight-loss responder rates.
Imcivree was approved in 2020 for rare genetic obesity, Bardet-Biedl syndrome was added in 2022, and the current label includes acquired hypothalamic obesity.
The label excludes general polygenic obesity and other non-labeled obesity types, confining evidence to diagnosed rare populations.
Research-market vials using the setmelanotide name have no established equivalence to the labeled 10 mg/mL product or its monitoring.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Current Imcivree prescribing information | Adults and pediatric patients meeting label criteria for acquired hypothalamic obesity, BBS, or POMC, PCSK1, or LEPR deficiency | FDA label and clinical-study summaries | Approved Imcivree product | The label defines the indications, limitations, once-daily subcutaneous route, starting amounts, titration logic, maintenance dosing, warnings, renal considerations, and product storage. | Label facts define Imcivree use. They do not answer compounded-product quality, research-market vial identity, ordinary-obesity benefit, cosmetic body-composition benefit, or non-label melanocortin claims. | Strong for labeled use |
| FDA 2020 rare genetic obesity approval | Patients six years and older with obesity due to POMC, PCSK1, or LEPR deficiency | FDA approval announcement summarizing two one-year studies | Approved Imcivree product | FDA described Imcivree as the first approved treatment for chronic weight management in those genetic conditions and reported 10 percent or greater body-weight-loss responders after one year. | FDA also stated that Imcivree is not approved for benign variants, other obesity types, other genetic syndromes, or general polygenic obesity. | Strong rare-disease human evidence |
| FDA 2022 Bardet-Biedl syndrome supplement | Adults and pediatric patients aged 6 years and older with obesity due to Bardet-Biedl syndrome | FDA supplemental approval announcement and phase 3 trial context | Approved Imcivree product | FDA described a 66-week trial, average BMI reduction after 52 weeks, and proportions of patients reaching at least 5 percent and 10 percent BMI reduction. | The BBS supplement does not cover unrelated syndromic obesity, ordinary obesity, non-approved products, or broader melanocortin claims. | Moderate to strong human evidence for BBS |
| Patient-reported outcomes in POMC and LEPR trials | People with obesity due to POMC or LEPR deficiency in the phase 3 program | Patient-reported outcome and quality-of-life analysis | Controlled rare-disease trial program | The paper adds hunger and quality-of-life outcomes alongside the rare-disease phase 3 program. | These outcomes remain tied to small, rare, pathway-defined cohorts; wellness appetite-control claims remain outside that evidence. | Limited human evidence |
Use context
Reported use context
Reported use is mostly label-derived. Imcivree is once-daily subcutaneous setmelanotide with titration by indication, age, tolerability, and renal function. Outside the approved settings, the same route language is often borrowed without the rare-disease diagnosis, product controls, or long-term labeling.
Real-world discussion
Discussion usually borrows once-daily label language while changing the goal to ordinary obesity or body composition. The reviewed material does not provide a dependable amount, frequency, or cycle for that use.
Listings or clinic claims may use the setmelanotide name while leaving concentration, sterility, endotoxin control, storage, and oversight different from Imcivree.
Cautions
Safety and unknowns
- Sexual-arousal disturbance is a visible label issue, including spontaneous penile erections and sexual adverse reactions in females.
- The label includes depression and suicidal ideation monitoring, which matters because this is a centrally acting appetite and satiety drug.
- Skin hyperpigmentation, darkening of existing nevi, and new melanocytic nevi can occur through melanocortin biology, so skin examination is part of the labeled monitoring.
- Serious hypersensitivity, including anaphylaxis, has been reported with Imcivree.
- Acquired hypothalamic obesity adds specific monitoring concerns for acute adrenal insufficiency and sodium imbalance in people with central diabetes insipidus or AVP deficiency.
- Severe renal impairment changes exposure and label recommendations. The label changes across ages, diagnoses, and kidney-function groups.
- The label and rare-disease studies leave ordinary-obesity, cosmetic-use, and non-approved-product safety questions open.
Product quality
A vial label is only a starting point
Imcivree is a 10 mg/mL approved sterile solution in a multiple-dose vial with labeled storage, handling, warnings, and adverse-event reporting.
A research-market, compounded, clinic, or vendor product using the setmelanotide name may differ in identity, concentration, sterility, endotoxin control, excipients, storage, shipment, and oversight.
Identity
The product has to be confirmed as setmelanotide, not just sold under the name.
Concentration
Imcivree is labeled as 10 mg/mL. A different concentration changes dose math and product comparison.
Sterility and endotoxin
A peptide purity statement does not address sterile manufacturing, endotoxin, storage, or multi-dose vial handling.
Storage and handling
The Imcivree label includes refrigeration, room-temperature limits, and discard timing after vial puncture; non-approved products may not have the same documented handling.
Labeling and monitoring
Imcivree labeling includes who the drug was studied for, warnings, contraindications, and monitoring instructions. A vendor listing or clinic summary may leave out those details.
Mechanism
How it is proposed to work
Setmelanotide activates MC4 receptors, part of a brain pathway that helps regulate hunger, fullness, and energy expenditure. In the labeled diseases, that pathway can be under-activated because of hypothalamic injury, syndromic obesity biology, or POMC, PCSK1, or LEPR pathway deficiency.
POMC, PCSK1, and LEPR sit upstream of melanocortin signaling, so an MC4 receptor agonist has a direct rationale when those rare pathway deficiencies drive severe early-onset obesity.
The DailyMed label describes setmelanotide as potentially restoring MC4 receptor pathway activity, reducing food intake and promoting weight loss through decreased caloric intake and increased energy expenditure in the labeled populations.
MC1 receptor activation helps explain skin pigmentation and nevi changes, which is why skin monitoring is not a cosmetic footnote.
The same mechanism that supports the rare-disease use does not carry ordinary polygenic obesity, cosmetic cutting, libido, tanning, or wellness use on its own.
FAQ
Common questions
Is setmelanotide a general weight-loss peptide?
No. The approved product is tied to specific rare-obesity contexts such as acquired hypothalamic obesity, Bardet-Biedl syndrome, and POMC, PCSK1, or LEPR deficiency. FDA sources explicitly separate it from general polygenic obesity.
Does Imcivree evidence apply to compounded or research-market setmelanotide?
No. The evidence and safety information are attached to a regulated approved product and defined trial populations. Product identity, sterility, labeling, excipients, and oversight cannot be assumed for non-approved products.
Why does genetic or disease-pathway diagnosis matter here?
Setmelanotide targets MC4-pathway biology. FDA and label language tie the evidence to specific pathway-deficiency or hypothalamic-obesity contexts, so diagnosis and label criteria are central to interpreting the evidence.
Details
Technical details
Sources
References
- 1.
DailyMed. IMCIVREE- setmelanotide solution prescribing information 2026.
Accessed 2026-06-09.
Current structured label source for Imcivree indications, limitations, mechanism, safety warnings, pediatric use, acquired hypothalamic-obesity context, and product identity.
- 2.
FDA. FDA approves first treatment for weight management for people with certain rare genetic conditions 2020.
Accessed 2026-06-09.
FDA approval announcement for Imcivree in obesity due to POMC, PCSK1, or LEPR deficiency, including the explicit boundary against general polygenic obesity.
- 3.
FDA. FDA approves treatment for weight management in patients with Bardet-Biedl Syndrome aged 6 or older 2022.
Accessed 2026-06-09.
FDA supplemental-indication announcement for Imcivree in Bardet-Biedl syndrome, including effectiveness and safety-summary context.
- 4.
PubMed. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency 2020.
doi:10.1016/S2213-8587(20)30364-8 PMID:33137293 Accessed 2026-06-09.
Single-arm, open-label, multicentre phase 3 trial evidence in severe obesity due to LEPR or POMC deficiency.
- 5.
doi:10.1016/S2213-8587(22)00277-7 PMID:36356613 Accessed 2026-06-09.
Randomized, double-blind, placebo-controlled phase 3 trial with an open-label period in Bardet-Biedl syndrome and Alstrom syndrome.
- 6.
PubMed. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency 2022.
doi:10.1186/s13023-022-02186-z PMID:35123544 Accessed 2026-06-09.
Quality-of-life and patient-reported outcome analysis alongside the POMC and LEPR phase 3 trial program.